Feeds:
Posts
Comments

Archive for the ‘FDA Regulatory Affairs’ Category

Human Factor Engineering: New Regulations Impact Drug Delivery, Device Design And Human Interaction

Curator: Stephen J. Williams, Ph.D.

Institute of Medicine report brought medical errors to the forefront of healthcare and the American public (Kohn, Corrigan, & Donaldson, 1999) and  estimated that between

44,000 and 98,000 Americans die each year as a result of medical errors

An obstetric nurse connects a bag of pain medication intended for an epidural catheter to the mother’s intravenous (IV) line, resulting in a fatal cardiac arrest. Newborns in a neonatal intensive care unit are given full-dose heparin instead of low-dose flushes, leading to threedeaths from intracranial bleeding. An elderly man experiences cardiac arrest while hospitalized, but when the code blue team arrives, they are unable to administer a potentially life-saving shock because the defibrillator pads and the defibrillator itself cannot be physically connected.

Human factors engineering is the discipline that attempts to identify and address these issues. It is the discipline that takes into account human strengths and limitations in the design of interactive systems that involve people, tools and technology, and work environments to ensure safety, effectiveness, and ease of use.

 

FDA says drug delivery devices need human factors validation testing

Several drug delivery devices are on a draft list of med tech that will be subject to a final guidance calling for the application of human factors and usability engineering to medical devices. The guidance calls called for validation testing of devices, to be collected through interviews, observation, knowledge testing, and in some cases, usability testing of a device under actual conditions of use. The drug delivery devices on the list include anesthesia machines, autoinjectors, dialysis systems, infusion pumps (including implanted ones), hemodialysis systems, insulin pumps and negative pressure wound therapy devices intended for home use. Studieshave consistently shown that patients struggle to properly use drug delivery devices such as autoinjectors, which are becoming increasingly prevalent due to the rise of self-administered injectable biologics. The trend toward home healthcare is another driver of usability issues on the patient side, while professionals sometimes struggle with unclear interfaces or instructions for use.

 

Human–factors engineering, also called ergonomics, or human engineering, science dealing with the application of information on physical and psychological characteristics to the design of devices and systems for human use. ( for more detail see source@ Britannica.com)

The term human-factors engineering is used to designate equally a body of knowledge, a process, and a profession. As a body of knowledge, human-factors engineering is a collection of data and principles about human characteristics, capabilities, and limitations in relation to machines, jobs, and environments. As a process, it refers to the design of machines, machine systems, work methods, and environments to take into account the safety, comfort, and productiveness of human users and operators. As a profession, human-factors engineering includes a range of scientists and engineers from several disciplines that are concerned with individuals and small groups at work.

The terms human-factors engineering and human engineering are used interchangeably on the North American continent. In Europe, Japan, and most of the rest of the world the prevalent term is ergonomics, a word made up of the Greek words, ergon, meaning “work,” and nomos, meaning “law.” Despite minor differences in emphasis, the terms human-factors engineering and ergonomics may be considered synonymous. Human factors and human engineering were used in the 1920s and ’30s to refer to problems of human relations in industry, an older connotation that has gradually dropped out of use. Some small specialized groups prefer such labels as bioastronautics, biodynamics, bioengineering, and manned-systems technology; these represent special emphases whose differences are much smaller than the similarities in their aims and goals.

The data and principles of human-factors engineering are concerned with human performance, behaviour, and training in man-machine systems; the design and development of man-machine systems; and systems-related biological or medical research. Because of its broad scope, human-factors engineering draws upon parts of such social or physiological sciences as anatomy, anthropometry, applied physiology, environmental medicine, psychology, sociology, and toxicology, as well as parts of engineering, industrial design, and operations research.

source@ Britannica.com

The human-factors approach to design

Two general premises characterize the approach of the human-factors engineer in practical design work. The first is that the engineer must solve the problems of integrating humans into machine systems by rigorous scientific methods and not rely on logic, intuition, or common sense. In the past the typical engineer tended either to ignore the complex and unpredictable nature of human behaviour or to deal with it summarily with educated guesses. Human-factors engineers have tried to show that with appropriate techniques it is possible to identify man-machine mismatches and that it is usually possible to find workable solutions to these mismatches through the use of methods developed in the behavioral sciences.

The second important premise of the human-factors approach is that, typically, design decisions cannot be made without a great deal of trial and error. There are only a few thousand human-factors engineers out of the thousands of thousands of engineers in the world who are designing novel machines, machine systems, and environments much faster than behavioral scientists can accumulate data on how humans will respond to them. More problems, therefore, are created than there are ready answers for them, and the human-factors specialist is almost invariably forced to resort to trying things out with various degrees of rigour to find solutions. Thus, while human-factors engineering aims at substituting scientific method for guesswork, its specific techniques are usually empirical rather than theoretical.

HFgeneralpic

 

 

 

 

 

 

 

 

 

 

 

The Man-Machine Model: Human-factors engineers regard humans as an element in systems

The simple man-machine model provides a convenient way for organizing some of the major concerns of human engineering: the selection and design of machine displays and controls; the layout and design of workplaces; design for maintainability; and the work environment.

Components of the Man-Machine Model

  1. human operator first has to sense what is referred to as a machine display, a signal that tells him something about the condition or the functioning of the machine
  2. Having sensed the display, the operator interprets it, perhaps performs some computation, and reaches a decision. In so doing, the worker may use a number of human abilities, Psychologists commonly refer to these activities as higher mental functions; human-factors engineers generally refer to them as information processing.
  3. Having reached a decision, the human operator normally takes some action. This action is usually exercised on some kind of a control—a pushbutton, lever, crank, pedal, switch, or handle.
  4. action upon one or more of these controls exerts an influence on the machine and on its output, which in turn changes the display, so that the cycle is continuously repeated

 

Driving an automobile is a familiar example of a simple man-machine system. In driving, the operator receives inputs from outside the vehicle (sounds and visual cues from traffic, obstructions, and signals) and from displays inside the vehicle (such as the speedometer, fuel indicator, and temperature gauge). The driver continually evaluates this information, decides on courses of action, and translates those decisions into actions upon the vehicle’s controls—principally the accelerator, steering wheel, and brake. Finally, the driver is influenced by such environmental factors as noise, fumes, and temperature.

 

hfactorconsideroutcomes

How BD Uses Human Factors to Design Drug-Delivery Systems

Posted in Design Services by Jamie Hartford on August 30, 2013

 Human factors testing has been vital to the success of the company’s BD Physioject Disposable Autoinjector.

Improving the administration and compliance of drug delivery is a common lifecycle strategy employed to enhance short- and long-term product adoption in the biotechnology and pharmaceutical industries. With increased competition in the industry and heightened regulatory requirements for end-user safety, significant advances in product improvements have been achieved in the injectable market, for both healthcare professionals and patients. Injection devices that facilitate preparation, ease administration, and ensure safety are increasingly prevalent in the marketplace.

Traditionally, human factors engineering addresses individualized aspects of development for each self-injection device, including the following:

  • Task analysis and design.
  • Device evaluation and usability.
  • Patient acceptance, compliance, and concurrence.
  • Anticipated training and education requirements.
  • System resilience and failure.

To achieve this, human factors scientists and engineers study the disease, patient, and desired outcome across multiple domains, including cognitive and organizational psychology, industrial and systems engineering, human performance, and economic theory—including formative usability testing that starts with the exploratory stage of the device and continues through all stages of conceptual design. Validation testing performed with real users is conducted as the final stage of the process.

To design the BD Physioject Disposable Autoinjector System , BD conducted multiple human factors studies and clinical studies to assess all aspects of performance safety, efficiency, patient acceptance, and ease of use, including pain perception compared with prefilled syringes.5 The studies provided essential insights regarding the overall user-product interface and highlighted that patients had a strong and positive response to both the product design and the user experience.

As a result of human factors testing, the BD Physioject Disposable Autoinjector System provides multiple features designed to aide in patient safety and ease of use, allowing the patient to control the start of the injection once the autoinjector is placed on the skin and the cap is removed. Specific design features included in the BD Physioject Disposable Autoinjector System include the following:

  • Ergonomic design that is easy to handle and use, especially in patients with limited dexterity.
  • A 360° view of the drug and injection process, allowing the patient to confirm full dose delivery.
  • A simple, one-touch injection button for activation.
  • A hidden needle before and during injection to reduce needle-stick anxiety.
  • A protected needle before and after injection to reduce the risk of needle stick injury.

 

YouTube VIDEO: Integrating Human Factors Engineering (HFE) into Drug Delivery

 

Notes:

 

 

The following is a slideshare presentation on Parental Drug Delivery Issues in the Future

 The Dangers of Medical Devices

The FDA receives on average 100,000 medical device incident reports per year, and more than a third involve user error.

In an FDA recall study, 44% of medical device recalls are due to design problems, and user error is often linked to the poor design of a product.

Drug developers need to take safe drug dosage into consideration, and this consideration requires the application of thorough processes for Risk Management and Human Factors Engineering (HFE).

Although unintended, medical devices can sometimes harm patients or the people administering the healthcare. The potential harm arises from two main sources:

  1. failure of the device and
  2. actions of the user or user-related errors. A number of factors can lead to these user-induced errors, including medical devices are often used under stressful conditions and users may think differently than the device designer.

Human Factors: Identifying the Root Causes of Use Errors

Instead of blaming test participants for use errors, look more carefully at your device’s design.

Great posting on reasons typical design flaws creep up in medical devices and where a company should integrate fixes in product design.
Posted in Design Services by Jamie Hartford on July 8, 2013

 

 

YouTube VIDEO: Integrating Human Factors Engineering into Medical Devices

 

 

Notes:

 

 Regulatory Considerations

  • Unlike other medication dosage forms, combination products require user interaction
  •  Combination products are unique in that their safety profile and product efficacy depends on user interaction
Human Factors Review: FDA Outlines Highest Priority Devices

Posted 02 February 2016By Zachary Brennan on http://www.raps.org/Regulatory-Focus/News/2016/02/02/24233/Human-Factors-Review-FDA-Outlines-Highest-Priority-Devices/ 

The US Food and Drug Administration (FDA) on Tuesday released new draft guidance to inform medical device manufacturers which device types should have human factors data included in premarket submissions, as well final guidance from 2011 on applying human factors and usability engineering to medical devices.

FDA said it believes these device types have “clear potential for serious harm resulting from use error and that review of human factors data in premarket submissions will help FDA evaluate the safety and effectiveness and substantial equivalence of these devices.”

Manufacturers should provide FDA with a report that summarizes the human factors or usability engineering processes they have followed, including any preliminary analyses and evaluations and human factors validation testing, results and conclusions, FDA says.

The list was based on knowledge obtained through Medical Device Reporting (MDRs) and recall data, and includes:

  • Ablation generators (associated with ablation systems, e.g., LPB, OAD, OAE, OCM, OCL)
  • Anesthesia machines (e.g., BSZ)
  • Artificial pancreas systems (e.g., OZO, OZP, OZQ)
  • Auto injectors (when CDRH is lead Center; e.g., KZE, KZH, NSC )
  • Automated external defibrillators
  • Duodenoscopes (on the reprocessing; e.g., FDT) with elevator channels
  • Gastroenterology-urology endoscopic ultrasound systems (on the reprocessing; e.g., ODG) with elevator channels
  • Hemodialysis and peritoneal dialysis systems (e.g., FKP, FKT, FKX, KDI, KPF ODX, ONW)
  • Implanted infusion pumps (e.g., LKK, MDY)
  • Infusion pumps (e.g., FRN, LZH, MEA, MRZ )
  • Insulin delivery systems (e.g., LZG, OPP)
  • Negative-pressure wound therapy (e.g., OKO, OMP) intended for home use
  • Robotic catheter manipulation systems (e.g., DXX)
  • Robotic surgery devices (e.g., NAY)
  • Ventilators (e.g., CBK, NOU, ONZ)
  • Ventricular assist devices (e.g., DSQ, PCK)

Final Guidance

In addition to the draft list, FDA finalized guidance from 2011 on applying human factors and usability engineering to medical devices.

The agency said it received over 600 comments on the draft guidance, which deals mostly with design and user interface, “which were generally supportive of the draft guidance document, but requested clarification in a number of areas. The most frequent types of comments requested revisions to the language or structure of the document, or clarification on risk mitigation and human factors testing methods, user populations for testing, training of test participants, determining the appropriate sample size in human factors testing, reporting of testing results in premarket submissions, and collecting human factors data as part of a clinical study.”

In response to these comments, FDA said it revised the guidance, which supersedes guidance from 2000 entitled “Medical Device Use-Safety: Incorporating Human Factors Engineering into Risk Management,” to clarify “the points identified and restructured the information for better readability and comprehension.”

Details

The goal of the guidance, according to FDA, is to ensure that the device user interface has been designed such that use errors that occur during use of the device that could cause harm or degrade medical treatment are either eliminated or reduced to the extent possible.

FDA said the most effective strategies to employ during device design to reduce or eliminate use-related hazards involve modifications to the device user interface, which should be logical and intuitive.

In its conclusion, FDA also outlined the ways that device manufacturers were able to save money through the use of human factors engineering (HFE) and usability engineering (UE).

– See more at: http://www.raps.org/Regulatory-Focus/News/2016/02/02/24233/Human-Factors-Review-FDA-Outlines-Highest-Priority-Devices/#sthash.cDTr9INl.dpuf

 

Please see an FDA PowerPoint on Human Factors Regulatory Issues for Combination Drug/Device Products here: MFStory_RAPS 2011 – HF of ComboProds_v4

 

 

 

 

Read Full Post »

Meeting Announcement: Cancer Immunotherapy and Combinations June 15-16 2016

Reporter: Stephen J. Williams, PhD

 

Cancer Immunotherapy & Combinations – June 15-16, 2016 in Boston, MA

YouTubeLinkedInTwitter#CHIWPC16

Final Brochure PDF | Learn More | Sponsorship & Exhibit Details | Register by March 4 & SAVE up to $400!

Cambridge Healthtech Institute’s inaugural Cancer Immunotherapy and Combinations meeting will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss next-generation approaches and combinations, including small molecule development, to enhance the efficacy of checkpoint inhibitors.

BISPECIFIC ANTIBODIES – DUAL TARGETING

FEATURED PRESENTATION: ANTI-PD1 OR CD137 ENHANCES NK-CELL CYTOTOXICITY TOWARDS CD30+ HODGKIN LYMPHOMA INDUCED BY CD30/CD16A TANDAB AFM13
Martin Treder, Ph.D., CSO, R&D, Affimed

In vivo Efficacy of Bispecific Antibodies Targeting Two Immune-Modulatory Receptors
Jacqueline Doody, Ph.D., Vice President, Immunology, F-star Biotechnology, Ltd

Dual-Targeting Bispecific Antibodies for Selective Neutralization of CD47 on Cancer Cells
Krzysztof Masternak, Ph.D., Head, Biology, Therapeutic Antibody Discovery, Novimmune

Update on MCLA-134: A Biclonics® Binding Two Immunomodulatory Targets Expressed by T Cells
Mark Throsby, Ph.D., CSO, Merus

The ImmTAC Technology: A Cutting-Edge Immunotherapy for Cancer Treatment
Samir Hassan, Ph.D., Director, Translational Research & Development, Immunocore Ltd.

RADIOTHERAPY AND CHEMOTHERAPY – PD-1 COMBINATIONS

Rational Development of Combinations of Antiangiogenic Therapy with Immune Checkpoint Blockers Using Mouse Models of HCC and Cirrhosis
Dan Duda, D.M.D., Ph.D., Associate Professor, Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School

Harnessing the Immune Microenvironment of Gastrointestinal Cancers Using Combined Modalities
Osama Rahma, M.D., Assistant Professor, Internal Medicine/Oncology, University of Virginia

AGONIST – PD-1 AND CTLA-4 COMBINATIONS

The Role of the Target in the Disposition and Immunogenicity of an Anti-GITR Agonist Antibody
Enrique Escandón, Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells
Changyu Wang, Ph.D., Director, Cancer Immunology, Pfizer

Combination Immunotherapy with Checkpoint Blockade, Agonist Anti-OX40 mAb, and Vaccination Rescues Anergic CD8 T Cells
William Redmond, Ph.D., Associate Member, Laboratory of Cancer Immunotherapy, Earle A. Chiles Research Institute, Providence Portland Medical Center

Interactive Breakout Discussion Groups with Continental Breakfast

This session features various discussion groups that are led by a moderator/s who ensures focused conversations around the key issues listed. Attendees choose to join a specific group and the small, informal setting facilitates sharing of ideas and active networking. Continental breakfast is available for all participants.

Topic: Small Molecule Targeting of IDO1 and TDO for Cancer Immunotherapy

Moderator: Rogier Buijsman, Ph.D., Head, Chemistry, Netherlands Translational Research Center B.V. (NTRC)

  • Overcoming challenges of current IDO1 inhibitors lacking selectivity over TDO and having suboptimal drug-like properties
  • Advances in IDO1 and TDO inhibitor screening
  • Is selective IDO1 or TDO inhibitors is required, or a dual IDO1/TDO inhibitor is preferred to obtain optimal efficacy and safety in the clinic?

Topic: Strategies for Developing Bispecific Antibodies for Cancer Immunotherapy

Moderator: Krzysztof Masternak, Ph.D., Head, Biology, Therapeutic Antibody Discovery, Novimmune

  • Considerations for efficacy in vitro and in vivo: selectivity for tumor cells, ADCP, ADCC, in vivo efficacy (xenograft models)
  • Insights into mechanisms of action
  • Safety considerations: binding selectivity, PK and tox studies

Topic: Combining Standard Antiangiogenic Therapy with Immune Checkpoint Inhibitors

Moderator: Dan Duda, D.M.D., Ph.D., Associate Professor, Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School

  • Will checkpoint combination with chemotherapy or other targeted agents prove to have too many toxicity issues?
  • How do we minimize overlapping toxic effects of radiation and immunotherapy?
  • How to optimize the sequencing of these two treatment modalities?

SMALL MOLECULE INHIBITORS AS SINGLE AND CHECKPOINT COMBINATION AGENTS

Selective Small Molecule Inhibitors of IDO1 and TDO for Cancer Immunotherapy
Rogier Buijsman, Ph.D., Head, Chemistry, Netherlands Translational Research Center B.V. (NTRC)

Potent and Selective Small Molecule USP7 Inhibitors for Cancer Immunotherapy
Suresh Kumar, Ph.D., Director, R&D, Progenra, Inc.

Epigenetic Agents for Combination with Cancer Immunotherapy
Svetlana Hamm, Ph.D., Head, Biology, Translational Pharmacology, 4SC Group

VACCINES AND CHECKPOINT BLOCKADE IMMUNOTHERAPY

Immunotherapy for Mesothelioma with an in vivo DC Vaccine and PD-1/PD-L1 Blockade
Huabiao Chen, M.D., Ph.D., Principal Investigator, Vaccine and Immunotherapy Center, Massachusetts General Hospital

Bringing Together Checkpoint Inhibition with Vaccines Using Customizing Capsids
Willie Quinn, Ph.D., President & CEO, Bullet Bio

Recommended All Access Package:

June 14 SC1: Immunosequencing: Generating a New Class of Cancer Immunotherapy Diagnostics*

June 14 SC5: Convergence of Immunotherapy and Epigenetics for Cancer Treatment*

June 14 SC8: Rational Design of Cancer Combination Therapies*

June 15-16: Cancer Immunotherapy and Combinations

June 16-17: Tumor Models for Cancer Immunotherapy

* Separate registration required.

Exhibit booth space has sold out! The few remaining spaces are being sold via sponsorship only. To customize yoursponsorship package, please contact:
Joseph Vacca, M.Sc., Associate Director, Business Development, 781-972-5431, jvacca@healthtech.com

For more information visit

WorldPreclinicalCongress.com/Cancer-Immunotherapy-Combinations

Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494 healthtech.com
Tel: 781-972-5400 | Fax: 781-972-5425

This email is being sent to sjwilliamspa@comcast.net. This email communication is for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.
Visit www.chicorporate.com/corporate_unsubscribe.aspx to update usage.

Read Full Post »

UPDATED on 2/25/2019

https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active

Medtronic recalled its dual chamber pacemakers (Adapta, Versa, Sensia, Relia, Attesta, Sphera, and Vitatron A, E, G, and Q series) due to a possible software error that can stop pacing.

Steps to minimise replacement of cardiac implantable electronic devices

Reporter: Aviva Lev-Ari, PhD, RN

Pacemaker battery scandal

SOURCE

http://www.bmj.com/content/352/bmj.i228

BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i228 (Published 04 February 2016)Cite this as: BMJ 2016;352:i228
  1. John Dean, consultant cardiologist 1,
  2. Neil Sulke, consultant cardiologist 2

Author affiliations

  1. Correspondence to: J Dean john.dean2@nhs.net

Much can and should be done to maximise the longevity of existing devices

Imagine spending £3000 on a new watch with a battery embedded in the mechanism that cannot be replaced or recharged. Although the battery is predicted to last 10 years or more, after six years you discover that it is running flat and you’re advised to replace the watch immediately, even though it may keep good time for a year or more.

This mirrors the dilemma faced by all patients with cardiac implantable electronic devices such as pacemakers and implantable cardioverter defibrillators (ICD). But for them the stakes are much higher as replacing the battery exposes them to a risk of serious complications, including life threatening infection.

Over half of all patients with pacemakers require a replacement procedure because the batteries have reached their expected life.1 Some 11-16% need multiple replacements.2 The situation is worse for recipients of an ICD, since the risks of infection at the time of implant and device replacement are higher than with pacemakers and the batteries have a shorter life.3

What is the risk of infection?

With no standard definition or reporting system, infection rates vary widely, and the commonly quoted risk of 0.5% for new implants and 1-5% for replacement procedures may be wrong.4 Infection, even if it seems superficial, usually necessitates extraction of the entire system. Simply treating the infection with antibiotics results in a much poorer outcome.5 The increased risk of infection associated with battery replacement makes it critical that we prolong the life of implantable devices as much as possible. The health economic grounds for minimising the number of replacements are also compelling.6

The current financial model discourages the development of longer life devices. Increasing longevity would reduce profits for manufacturers, implanting physicians, and their institutions. With financial disincentives for both manufacturers and purchasers it is hardly surprising that longer life devices do not exist.

Patients are often assumed to prefer smaller devices, but when offered the choice, over 90% would opt for a larger, longer lasting device over a smaller one that would require more frequent operations to change the battery.7 And given the risks that patients are exposed to during replacement, there is an urgent need to improve longevity by developing longer life batteries and using those in current devices more prudently.

What can be done now?

At present the main drive to improving longevity of pacemakers has been through programming changes aimed at reducing the amount of pacing8 or minimising the drain of current during pacing—for example, using high impedance leads. But devices are usually replaced when there is still substantial life left in the battery. For example, when a pacemaker reaches elective replacement indication, it is usually 3-12 months before it will reach its end of life. And even then, the battery may continue to function for several months. Early replacement may be reasonable for high risk patients (such as those who are entirely dependent on their pacemaker). However, we could delay replacement of the pulse generator until the batteries are virtually depleted in lower risk patients. The increasingly popular innovation of home monitoring of devices would facilitate this.

For ICDs the waste is even more striking; devices reach their elective replacement indication when they are still capable of delivering at least six full energy shocks. Each shock reduces the battery longevity by about 30 days. So for patients who receive no shock therapy we are prematurely discarding a device costing up to £25 000 (€33 000; $36 000), which could last at least another six months (current devices last four to seven years on average). We need to review the timing of replacement of implantable devices in all patients.

CONTINUE READING

http://www.bmj.com/content/352/bmj.i228

REFERENCES

  1. ↵
  2. ↵
  3. ↵
  4. ↵
  5. ↵
  6. ↵
  7. ↵
  8. ↵

Read Full Post »

BioMEMS The Market aspects of Oligonucleotide-Chips, Products and Applications, Competition, January 21, 2016

Curator: Gérard LOISEAU, ESQ

 

BioMEMS

The Market aspects of Oligonucleotide-Chips, Products, Applications, Competition 

January 21, 2016

2015-2020

The oligonucleotide synthesis market is expected to reach USD 1.918.6Billion at a CAGR of 10.1% by 2020 from USD 1.078.1Billion in 2015.

SOURCE

MARKETSANDMARKETS marketsandmarkets.com/

 

PLAYERS

  • Agilent Technologies Inc.
  • BioAutomation Corp.
  • Biosearch Technologies
  • Gen9 Inc.
  • GenScript Inc.
  • Illumina Inc.
  • Integrated DNA Technologies
  • New England Biolabs Inc.
  • Nitto Denko Avecia Inc.
  • OriGene Technologies Inc.
  • Sigma-Aldrich Corporation
  • Thermo Fisher Scientific Inc.
  • TriLink Biotechnologies

 

Agilent Technologies
 CA NYSE :A


http://www.agilent.com/

  • Agilent was created as a spin off from Hewlett-Packard Company in 1999.
  • Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments:

the life sciences and applied markets business,

the diagnostics and genomics business, and

the Agilent Cross Lab business

  • The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics.
  • The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business.
  • The Company’s Agilent Cross Lab business segment combines its analytical laboratory services and consumables business

SOURCE

http://reuters.com/

PRODUCTS AND SERVICES

https://www.agilent.com/en-us/default#collapse-0

  • October 09, 2015 03:21 PM Eastern Daylight Time
  • CARPINTERIA, Calif.–(BUSINESS WIRE)–Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC.

SOURCE

BUSINESS WIRE busibesswire.com/

 

BioAutomation Corp.

 TX


 

http://bioautomation.com/

          PRODUCTS AND SERVICES

  • DNA and RNA synthesis reagents for the MerMades

 

Note: The MerMade 192E Oligonucleotide synthesizer is designed to synthesize DNA, RNA & LNA oligonucleotides in a column format

          PARTNERSHIPS

  • HONGENE BIOTECH : BIOAUTOMATION is the exclusive distributor for the Americas
  • EMD MILLIPORE
  • BIOSEARCH TECHNOLOGIES

 

DISTRIBUTORS

  • LINK TECHNOLOGIES : UK
  • AME BIOSCIENCE : UK
  • BOSUNG SCIENCE : KOREA
  • DNA CHEM : CHINA
  • WAKO : JAPAN
  • ACE PROBE : INDIA

SOURCE

bioautomation.com/

 

Biosearch Technologies
 CA


http://biosearchtech.com/

          PRODUCTS

  • qPCR & SNP Genotyping
  • Custom Oligonucleotides
  • – highly sophisticated oligonucleotides
  • – simple PCR primers
  • Oligos in Plates
  • RNA FISH
  • Synthesis Reagents
  • Immunochemicals
  • Primers
  • Probes
  • Large-Scale Synthesis Oligos
  • Intermediate-Scale Synthesis Oligos

          SERVICES

  • GMP & Commercial Services
  • OEM & Kit Manufacturing
  • qPCR Design Collaborations

          DISTRIBUTORS

Argentina | Australia | Austria | Brazil | Canada |Chile | China | Colombia | Czech Republic | Denmark | Ecuador | Finland | Germany |Hong Kong | Israel | Italy | Japan | Korea | Malaysia | Mexico | New Zealand | Norway | Paraguay | Peru| Philippines | Poland | Romania | Singapore | South Africa | Spain | Sweden |Switzerland | Taiwan ROC | Thailand | Turkey | United Kingdom | Uruguay | Vietnam

SOURCE

biosearchtech.com/

 

Gen9 Inc.
 MA 


http://www.gen9bio.com/

          PRODUCTS

Gen9 is building on advances in synthetic biology to power a scalable fabrication capability that will significantly increase the world’s capacity to produce DNA content. The privately held company’s next-generation gene synthesis technology allows for the high-throughput, automated production of DNA constructs at lower cost and higher accuracy than previous methods on the market. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels.

          SERVICES

  • Synthetic Biology
  • Gene Synthesis Services
  • Variant Libraries
  • Gene Sequence Design Services

         INVESTORS

  • Agilent Technologies : Private Equity
  • CAMBRIDGE, Mass. and SANTA CLARA, Calif. — April 24, 2013 —Gen9 Receives $21 Million Strategic Investment from Agilent Technologies

SOURCE

gen9bio.com/

 

GenScript Inc.
 NJ 


http://www.genscript.com/

  • GenScript is the largest gene synthesis provider in the USA
  • GenScript Corporation, a biology contract research organization, provides biological research and drug discovery services to pharmaceutical companies, biotech firms, and research institutions in the United States, Europe, and Japan. It offers bio-reagent, custom molecular biology, custom peptide, protein production, custom antibody production, drug candidates testing, assay development and screening, lead optimization, antibody drug development, gene synthesis, and assay-ready cell line production services.
  • The company also offers molecular biology, peptide, protein, immunoassay, chemicals, and cell biology products. It offers its products through distributors in Tokyo, Japan; and Seoul, Korea. GenScript Corporation has a strategic partnership with Immunologix, Inc. The company was founded in 2002 and is based in Piscataway, New Jersey. It has subsidiaries in France, Japan, and China.

 

Note: As of October 24, 2011, Immunologix, Inc. was acquired by Intrexon Corporation. Immunologix, Inc. develops and produces antibody-based therapeutics for various biological targets. It produces human monoclonal antibodies against viral, bacterial, and tumor antigens, as well as human auto antigens.

Intrexon Corporation, founded in 1998, is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment and Consumer sectors to create biologically based products that improve quality of life and the health of the planet.

 

 

             PRODUCTS AND SERVICES

  • Gene synthesis
  • Antibody services
  • Protein Services
  • Peptide services

 

               INVESTORS


Note: The Balloch Group (‘TBG’) was established in 2001 by Howard Balloch (Canada‘s ambassador to China from 1996 to 2001). TBG has since grown from a market-entry consultancy working with North American clients in China to a leading advisory and merchant banking firm serving both domestic Chinese companies and multinational corporations. TBG was ranked as the number one boutique investment bank in China by ChinaVenture in 2008.

Kleiner, Perkins, Caufield and Byers

 

Illumina
Inc. CA


http://illumina.com/

 

Monica Heger : SAN FRANCISCO (GenomeWeb) – Illumina today announced two new next-generation sequencing platforms, a targeted sequencing system called MiniSeq and a semiconductor sequencer that is still under development.

Illumina disclosed the initiatives during a presentation at the JP Morgan Healthcare conference held here today. During the presentation, Illumina CEO Jay Flatley also announced a new genotyping array called Infinium XT; a partnership with Bio-Rad to develop a single-cell sequencing workflow; preliminary estimates of its fourth-quarter 2015 revenues; and an update on existing products. The presentation followed the company’s announcement on Sunday that it has launched a new company called Grail to develop a next-generation sequencing test for early cancer detection from patient blood samples.

The MiniSeq system, which is based on Illumina’s current sequencing technology, will begin shipping early this quarter and has a list price of $49,500. It can perform a variety of targeted DNA and RNA applications, from single-gene to pathway sequencing, and promises “all-in” prices, including library prep and sequencing, of $200 to $300 per sample, Flatley said during the JP Morgan presentation.

SOURCES

https://www.genomeweb.com/sequencing-technology/illumina-unveils-mini-targeted-sequencer-semiconductor-sequencing-project-jp

http://investor.biospace.com/biospace/quote?Symbol=ILMN

 

              PRODUCTS AND SERVICES

  •               Mid to large scale manufacturing assets
  •               Analytical Labs
  •               Pre-clinical
  •               Clinical
  •               Launched products

 

              COMPETITORS

https://finance.yahoo.com/q/co?s=ILMN+Competitors Tue, Feb 2, 2016, 2:16pm EST – US Markets

ILMN PVT1 AFFX LMNX Industry
Market Cap: 22.75B N/A 1.13B 835.66M 134.14M
Employees: 3,700 10,000 1,200 745 45.00
Qtrly Rev Growth (yoy): 0.14 N/A -0.01 0.07 0.18
Revenue (ttm): 2.14B 3.80B1 357.74M 235.37M 8.47M
Gross Margin (ttm): 0.73 N/A 0.63 0.71 0.58
EBITDA (ttm): 770.84M N/A 46.64M 52.99M -12.31M
Operating Margin (ttm): 0.30 N/A 0.08 0.17 -1.62
Net Income (ttm): 510.36M 430.90M1 11.22M 39.29M N/A
EPS (ttm): 3.42 N/A 0.13 0.93 -0.34
P/E (ttm): 45.43 N/A 104.40 20.91 25.33
PEG (5 yr expected): 2.68 N/A 4.66 0.55 N/A
P/S (ttm): 10.87 N/A 3.13 3.45 13.65

 

Pvt1 = Life Technologies Corporation (privately held)

AFFX = Affymetrix Inc.

LMNX = Luminex Corporation

 

 

Integrated DNA Technologies (IDT)
IOWA + CA

http://www.com/

 

Integrated DNA Technologies, Inc. (IDT), the global leader in nucleic acid synthesis, serving all areas of life sciences research and development, offers products for a broad range of genomics applications. IDT’s primary business is the production of custom, synthetic nucleic acids for molecular biology applications, including qPCR, sequencing, synthetic biology, and functional genomics. The company manufactures and ships an average of 44,000 custom nucleic acids per day to more than 82,000 customers worldwide. For more information, visit idtdna.com.

 

               PRODUCTS AND SERVICES

               https://eu.idtdna.com/site

  • DNA & RNA Synthesis
  • Custom DNA Oligos 96- & 384-Well Plates Ultramer Oligos Custom RNA Oligos SameDay Oligos HotPlates ReadyMade Primers Oligo Modifications Freedom
  • Dyes GMP for Molecular Diagnostics Large Scale Oligo Synthesis

 

Note : Skokie, IL – December 1, 2015. Integrated DNA Technologies Inc. (“IDT”), the global leader in custom nucleic acid synthesis, has entered into a definitive agreement to acquire the oligonucleotide synthesis business of AITbiotech Pte. Ltd. in Singapore (“AITbiotech”). With this acquisition, IDT expands its customer base across Southeast Asia making it possible for these additional customers to now have access to its broad range of products for genomic applications. AITbiotech will continue operations in its other core business areas.

 

New England Biolabs Inc.
 MA 


http://www.neb.com/

 

                PRODUCTS AND SERVICES

  •                 Restriction Endonucleases
  •                 PCR, Polymerases & Amplification Technologies
  •                 DNA Modifying Enzymes
  •                 Library Preparation for Next Generation Sequencing
  •                 Nucleic Acid Purification
  •                 Markers & Ladders
  •                 RNA Reagents
  •                 Gene Expression
  •                 Cellular Analysis

SOURCE

neb.com/

 

Nitto Denko Avecia Inc.
 MA


http://avecia.com/

 

With over 20 years of experience in oligonucleotide development and production, and over 1000 sequences manufactured, Avecia has played an integral role in the advancing oligo therapeutic market. Our mission is to continue to build value for our customers, as they progress through drug development into commercialization. And as a member of the Nitto Denko Corporation (nitto.com), Avecia is committed to the future of the oligonucleotide market. We are driven by innovative ideas and flexible solutions, designed to provide our customers with the best in service, quality, and technology.

 

SOURCE

http://avecia.com/

 

Note : 1918 Nitto Electric Industrial Co., Ltd. forms in Ohsaki, Tokyo, to produce electrical insulating materials in Japan.

2011 Acquires Avecia Biotechnology Inc. in the U.S.A.

 

 

OriGene Technologies Inc.
 CA

http://www.com/

 

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products for pharmaceutical, biotechnology, and academic research applications. The company offers cDNA clones, including TrueORF cDNA, viral ORF, destination vectors, TrueClones (human), TrueClones (mouse), organelle marker plasmids, MicroRNA tools, mutant and variant clones, plasmid purification kits, transfection reagents, and gene synthesis service; and HuSH shRNA, siRNA, miRNA, qPCR reagents, plasmid purification products, transfection reagents, PolyA+ and total RNA products, first-strand cDNA synthesis, and CRISPR/Cas9 genome products. It also provides proteins and lysates, such as purified human proteins, over-expression cell lysates, mass spectrometry standard proteins, and protein purification reagents; UltraMAB IHC antibodies, TrueMAB primary antibodies, anti-tag and fluorescent proteins, ELISA antibodies, luminex antibodies, secondary antibodies, and controls and others; and anatomic pathology products, including IHC antibodies, detection systems, and IHC accessories

The company offers luminex and ELISA antibody pairs, autoantibody profiling arrays, ELISA kits, cell assay kits, assay reagents, custom development, and fluorogenic cell assays; TissueFocus search tools; tissue sections; tissue microarrays, cancer protein lysate arrays, TissueScan cDNA arrays, tissue blocks, and quality control products, as well as tissue RNA, DNA, and protein lysates; and lab essentials. Its research areas include cancer biomarker research, RNAi, pathology IHC, stem cell research, ion channels, and protein kinase products. The company provides gene synthesis and molecular biology services, genome editing, custom cloning, custom shRNA, purified protein, monoclonal antibody development, and assay development. It sells its products through distributors worldwide, as well as online. OriGene Technologies, Inc. was incorporated in 1995 and is based in Rockville, Maryland.

SOURCE

http://BLOOMBERG.com

               PRODUCTS AND SERVICES

  •                cDNA Clones
Human, mouse, rat
Expression validated
  •                RNAi
shRNA, siRNA
microRNA & 3’UTR clones
  •                Gene Synthesis
Codon optimization
Variant libraries
  •                Real-time PCR
Primer pairs, panels
SYBR green reagents
  •                Lab Essentials
DNA/RNA purification kits
Transfection reagents
  •                Anatomic Pathology
UltraMAB antibodies
Specificity validated
  •                Recombinant Proteins
10,000 human proteins
from mammalian system
  •                Antibodies
TrueMAB primary antibodies
Anti-tag antibodies
  •                Assays and Kits
ELISA & Luminex antibodies
Autoantibody Profiling Array
  •                Cancer & Normal Tissues
Pathologist verified
gDNA, RNA, sections, arrays

SOURCE

origene.com/

 

Sigma-Aldrich Corporation 
MI 


http://www.sigmaaldrich.com/

Louis, MO – November 18, 2015 Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition

Merck KGaA today announced the completion of its $17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $130 billion global industry to help solve the toughest problems in life science.

Press Release: 18-Nov-2015

Letter to our Life Science Customers from Dr. Udit Batra

The life science business of Merck KGaA, Darmstadt, Germany brings together the world-class products and services, innovative capabilities and exceptional talent of EMD Millipore and Sigma-Aldrich to create a global leader in the life science industry.

“Everything we do starts with our shared purpose – to solve the toughest problems in life science by collaborating with the global scientific community. 

This combination is built on complementary strengths, which will enable us to serve you even better as one organization than either company could alone.

This means providing a broader portfolio with a catalog of more than 300,000 products, including many of the most respected brands in the industry, greater geographic reach, and an unmatched combination of industry-leading capabilities.”

                PRODUCTS AND SERVICES

                http://www.sigmaaldrich.com/configurator/servlet/DesignCenter?btnOpen_0.x=1

                http://www.sigmaaldrich.com/content/dam/sigma-aldrich/common/quality-products.jpg

 

Thermo Fisher Scientific Inc.
 MA 
NYSE :TMO


http://thermofisher.com/


Thermo Fisher Scientific Inc. is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, provides instruments, consumables, software and services that are used in the laboratory; Specialty Diagnostics, offers diagnostic test kits, reagents, culture media, instruments and associated products, and Laboratory Products and Services, offers self-manufactured and sourced products for the laboratory.

SOURCE

http://REUTERS.com

 

                PRODUCTS AND SERVICES

  •                 Oligos Value – Standard – Plate
  •                 Primers
  •                 Probes
  •                 Nucleotides

 

                BRANDS

  1.                THERMO SCIENTIFIC
  2.                 APPLIED BIOSYSTEMS
  3.                 INVITROGEN
  4.                 FISHER SCIENTIFIC
  5.                 UNITY LAB SERVICES

 

                 PARTNERSHIPS

AFFYMETRIX : NASDAQ : AFFX : affymetrix.com/

WALTHAM, Mass. & SANTA CLARA, Calif.–(BUSINESS WIRE)–Jan. 8, 2016– Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and Affymetrix Inc. (NASDAQ:AFFX), a leading provider of cellular and genetic analysis products, today announced that their boards of directors have unanimously approved Thermo Fisher’s acquisition of Affymetrix for $14.00 per share in cash. The transaction represents a purchase price of approximately $1.3 billion.

SOURCE

http://BUSINESSWIRE.com

 

TriLink Biotechnologies
 CA 


http://www.com/

 

              PRODUCTS

              Oligonucleotides

  •               DNA Oligos
  •               RNA Oligos
  •               Modified Oligos
  •               Specialty Oligos

              Nucleotides

  •               NTPs (Nucleoside Triphosphates)
  •               Biphosphates
  •               Monophosphates

 

              SERVICES

  •              Custom Chemistry
  •              Reagents
  •              Aptamers

 

             PARTNERSHIPS

  • LIFE TECHNOLOGIES,
  • TERMO FISHER SCIENTIFIC since July 2015 thermofisher.com/
  • GENMARK genmarkdx.com/

SOURCE

http://trilinkbiotech.com/

 

Other related articles published in this Open Access Online Scientific Journal include the following:

Gene Editing: The Role of Oligonucleotide Chips

http://pharmaceuticalintelligence.com/2016/01/07/gene-editing-the-role-of-oligonucleotide-chips/

Gene Editing for Exon 51: Why CRISPR Snipping might be better than Exon Skipping for DMD

http://pharmaceuticalintelligence.com/2016/01/23/gene-editing-for-exon-51-why-crispr-snipping-might-be-better-than-exon-skipping-for-dmd/

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Read Full Post »

New Guidelines by FDA in the Medical Devices Space: FDA Releases Guidance On In Vitro Companion Diagnostic Devices

Reporter: Aviva Lev-Ari, PhD, RN

 

New Guidelines by FDA in the Medical Devices Space

 

SOURCE

http://www.meddeviceonline.com/doc/fda-issues-final-guidance-for-k-devices-labeled-as-sterile-0001?s

Read Full Post »

More Than 25 Percent of the Novel New Drugs Approved by FDA in 2015 are Personalized Medicines

Reporter: Aviva Lev-Ari, PhD, RN

A new analysis from the Personalized Medicine Coalition (PMC) documents an upward trend in the number of personalized medicine approvals at FDA, with personalized medicines accounting for more than 1 in 4 novel new drugs (NNDs) approved in 2015.

The analysis, titled 2015 Progress Report: Personalized Medicine at FDA, lists the 13 personalized medicines approved as NNDs in 2015, which represent 28 percent of the 45 NNDs the agency approved overall. The new approvals accelerate a trend PMC first noted in 2014, when the Coalition classified 21 percent of the year’s NNDs as personalized medicines.

PMC Science Policy Vice President Daryl Pritchard, Ph.D., said the momentum is driven by scientific validation of personalized medicine’s ability to improve patient outcomes.

“The scientific community has established personalized medicine as a successful approach to treating many diseases,” Pritchard said. “The increasing number of approvals for these drugs reflects that progress.”

SOURCE

http://www.pharmpro.com/news/2016/01/many-novel-drugs-approved-fda-2015-are-personalized-medicines

 

2015 Progress Report Personalized Medicine at FDA

 

More Than 25 Percent of the Novel New Drugs Approved by FDA in 2015 are Personalized Medicines

The transformation of health care from one-size-fits-all, trial-and-error medicine to a targeted approach utilizing an individual patient’s molecular information continues to accelerate as the U.S. Food and Drug Administration (FDA) more regularly and rapidly approves new personalized medicines. FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel new drugs (NNDs), either

new molecular entities or new therapeutic biologics, in 2015. Of these 45 NNDs, 13 of them — more than 25 percent — were personalized medicines as classified by the Personalized Medicine Coalition (PMC), thus continuing a trend that began last year when nine of 41 NNDs were classified as personalized medicines.

 

SOURCE

http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/2015_Progress_Report_PM_at_FDA.pdf

 

Read Full Post »

Clinical Trials Could Lead to FDA Approval for Artificial Pancreas

 Reporter: Irina Robu, PhD

Approximately 1.25 million American have type 1 diabetes accroding to the U.S. Centers for Disease Control and Prevention. A device that automatically monitors and regulates blood-sugar levels in people with type 1 diabetes developed by University of Virginia School of Medicine undergo two clinical trials starting early 2016.

The goal of the artificial pancreas is to eliminate the need for people with type 1 diabetes to stick their fingers multiple times daily to check their blood-sugar levels and to inject insulin manually.The artificial pancreas is designed to oversee and adjust insulin delivery as needed. At the center of the artificial pancreas platform is a reconfigured smartphone running advanced algorithms that is linked wirelessly to a blood-sugar monitor and an insulin pump, as well as a remote-monitoring site. People with the artificial pancreas can also access assistance via telemedicine.

Beneficial results from these long-term clinical trials examining how the artificial pancreas works in real-life settings could lead the U.S. Food and Drug Administration and other international regulatory groups to approve the device for use by people with type 1 diabetes, whose bodies do not produce enough insulin. The trials will conducted at nine locations in the U.S. and Europe sustained by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.

The first study – the International Diabetes Closed-Loop trial – will test technology developed at UVA by a research team led by Boris Kovatchev, director of the UVA Center for Diabetes Technology. That technology has been refined for clinical use by TypeZero Technologies, a startup company in Charlottesville that has licensed the UVA system. The second trial will examine a new control algorithm developed by the team of Dr. Francis Doyle III at the Harvard John A. Paulson School of Engineering and Applied Sciences to test whether it further improves control of blood-sugar levels.

Along with UVA, the artificial pancreas will be tested at eight additional sites: Harvard University, Mount Sinai School of Medicine, Mayo Clinic, University of Colorado, Stanford University, University of Montpellier in France, University of Padova in Italy and Academic Medical Center at the University of Amsterdam in The Netherlands.

SOURCE

Read Full Post »

Cardiology & Oncology Drug Development & Regulation

Authors: Stuart L. Cantor, PhD, and Kadriye Ciftci, PhD

 

 

Cardiology & Oncology Drug Development & Regulation

Stuart L. Cantor, PhD, and Kadriye Ciftci, PhD, discuss the road to development and regulatory approval associated with two of the leading therapeutic focus markets: cardiology and oncology.

SOURCE

http://www.drug-dev.com/Main/Back-Issues.aspx?issueid=c8951f73-08d9-4f15-bd1f-6e4f2c3d3ade#sthash.XIc7G4OM.dpuf

 

 

Read Full Post »

FDA – What is the Status of the Technologies of “Precision Medicine”?

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

Session 2: FDA – What is the status of the technologies of “precision medicine”?

VIEW VIDEO

http://www.youtube.com/watch?v=tCP91nvbgI4

Read Full Post »

FDA Drug Approvals in 2014: Drug Indication, Approval Date, Pharma, Agent Type and Drug Name

Curator: Stephen J Williams, PhD

Summary of 2014 FDA Approvals

Small Molecules versus Biologics

Below is a summary of the 2014 FDA Approvals with respect to their classification as small molecule or biologic. Data is taken from the FDA website https://www.centerwatch.com/drug-information/fda-approved-drugs/year/2014

In molecular biology and pharmacology, a small molecule is a low molecular weight (<900 daltons) organic compound that may help regulate a biological process, with a size on the order of 10−9 m. Most drugs are small molecules.

From the FDA Biological products, or biologics, are medical products. Many biologics are made from a variety of natural sources (human, animal or microorganism). Like drugs, some biologics are intended to treat diseases and medical conditions. Other biologics are used to prevent or diagnose diseases. Examples of biological products include:
• vaccines
• blood and blood products for transfusion and/or manufacturing into other products
• allergenic extracts, which are used for both diagnosis and treatment (for example, allergy shots)
• human cells and tissues used for transplantation (for example, tendons, ligaments and bone)
• gene therapies
• cellular therapies
• tests to screen potential blood donors for infectious agents such as HIV

CONCLUSIONS:

As shown there were 106 small molecules approved and 59 biologics approved in 2014.

  • Sales figures were or their anticipated market size as well as cost/benefit analysis.   This was mentioned as a very important requirement in drug development by JNJ. The pharmacy benefit managers, insurers and the pharma companies said they were talked early in the drug development process using cost/benefit analysis as a criteria of go/ no go decision point.
  • The insurers are very cost conscious as well as the PBMs. There are some classes that had mainly biologics and this was not oncology. In addition inflammation had lots more small molecule. The breakdown seems to be more meaningful than the totals and there are many reformulations and double indications.
Cardiology/Vascular Diseases (2 small molecules)
Drug Indication Pharma drug type Drug Name Approval Date
For the treatment of severe hypertriglyceridemia AstraZeneca small molecule Epanova (omega-3-carboxylic acids) May-14
For the reduction of thrombotic cardiovascular events Merck small molecule Zontivity (vorapaxar); May-14
Dermatology 7 small molecules 2 biologics
For the treatment of acute bacterial skin and skin structure infections Durata Therapeutics synthetic small molecule Dalvance (dalbavancin); May-14
For the treatment of onychomycosis of the toenails Valeant Pharmaceuticals synthetic small molecule Jublia (efinaconazole) 10% topical gel Jun-14
For the treatment of onychomycosis of the toenails Anacor synthetic small molecule Kerydin (tavaborole) Jul-14
For the treatment of unresectable or metastatic melanoma Merck biologic Keytruda (pembrolizumab) Sep-14
For the treatment of unresectable or metastatic melanoma Bristol-Myers Squibb biologic Opdivo (nivolumab) Dec-14
For the treatment of acute bacterial skin and skin structure infections The Medicines Company semisynthetic small molecule Orbactiv (oritavancin) Aug-14
For the treatment of moderate to severe plaque psoriasis Celgene small molecule Otezla (apremilast) Sep-14
For the treatment of acute bacterial skin and skin structure infections Cubist Pharmaceuticals small molecule Sivextro (tedizolid phosphate) Jun-14
For the treatment of inflammatory lesions of rosacea Galderma Labs semisynthetic small molecule Soolantra (ivermectin) cream, 1% Dec-14
Endocrinology 6 small molecules 4 biologics
For the treatment of diabetes mellitus Mannkind biologic Afrezza (insulin human) Inhalation Powder Jun-14
For the treatment of hypogonadism Endo Pharmaceuticals small molecule Aveed (testosterone undecanoate) injection Mar-14
For the treatment of type II diabetes Bristol-Myers Squibb small molecule Farxiga (dapagliflozin) Jan-14
For the treatment of type II diabetes Boehringer Ingelheim small molecule Jardiance (empagliflozin) Aug-14
For the treatment of deficiency or absence of endogenous testosterone Trimel Pharmaceuticals small molecule Natesto, (testosterone) nasal gel May-14
For the treatment of acromegaly Novartis biologic Signifor LAR (pasireotide) Dec-14
For the treatment of type II diabetes mellitus GlaxoSmithKline biologic Tanzeum (albiglutide) Apr-14
To improve glycemic control in type II diabetics Eli Lilly biologic Trulicity (dulaglutide) Sep-14
For males with a deficiency or absence of endogenous testosterone Upsher-Smith synthetic small molecule Vogelxo (testosterone) gel Jun-14
For glycemic control in adults with type II diabetes AstraZeneca small molecule Xigduo XR (dapagliflozin + metformin hydrochloride) Oct-14
Family Medicine 21 small molecules 11 biologics
For the treatment of diabetes mellitus Mannkind biologic Afrezza (insulin human) Inhalation Powder; Jun-14
For the treatment of hemophilia B Biogen Idec biologic Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] Mar-14
For the treatment of asthma, GlaxoSmithKline small molecule Arnuity Ellipta (fluticasone furoate inhalation powder) Aug-14
For the treatment of hypogonadism Endo Pharmaceuticals small molecule Aveed (testosterone undecanoate) injection; Mar-14
For the treatment of insomnia Merck small molecule Belsomra (suvorexant) Aug-14
For the maintenance treatment of opioid dependence BioDelivery Sciences small molecule Bunavail (buprenorphine and naloxone) Jun-14
For chronic weight management Takeda Pharmaceuticals U.S.A small molecule Contrave (naltrexone HCl and bupropion HCl) Sep-14
For the treatment of acute bacterial skin and skin structure infections Durata Therapeutics semisynthetic small molecule Dalvance (dalbavancin) May-14
For the management of mild, moderate or severe pain Hospira small molecule Dyloject (diclofenac sodium) Injection Dec-14
For the treatment of adults with ulcerative colitis and Crohn’s disease Millenium Pharmaceuticals biologic Entyvio (vedolizumab) May-14
For the treatment of type II diabetes Bristol-Myers Squibb small molecule Farxiga (dapagliflozin) Jan-14
For the treatment of grass pollen-induced allergic rhinitis Merck biologic Grastek (Timothy Grass Pollen Allergen Extract) Apr-14
For the treatment of type II diabetes Boehringer Ingelheim small molecule Jardiance (empagliflozin) Aug-14
For the treatment of onychomycosis of the toenails Anacor small molecule Kerydin (tavaborole) Jul-14
For the treatment of bacterial vaginosis Actavis, Inc semisynthetic small molecule Metronidazole 1.3% Vaginal Gel Apr-14
For the treatment of congenital or acquired generalized lipodystrophy Bristol-Myers Squibb biologic Myalept (metreleptin for injection) Feb-14
For the treatment of deficiency or absence of endogenous testosterone Trimel Pharmaceuticals semisynthetic small molecule Natesto, (testosterone) nasal gel; May-14
For the treatment of neurogenic orthostatic hypotension Chelsea Therapeutics synthetic small molecule Northera (droxidopa) Feb-14
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis, Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) Apr-14
For the treatment of adults with active psoriatic arthritis Celgene small molecule Otezla (apremilast) Mar-14
For the treatment of moderate to severe plaque psoriasis Celgene small molecule Otezla (apremilast) Sep-14
For the treatment of relapsing multiple sclerosis Biogen Idec biologic Plegridy (peginterferon beta-1a) Aug-14
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome Upsher-Smith Laboratories small molecule Qudexy XR (topiramate) Mar-14
For the treatment of short ragweed pollen-induced allergic rhinitis Merck biologic Ragwitek (Short Ragweed Pollen Allergen Extract) Apr-14
For the treatment of acute uncomplicated influenza in adults Biocryst small molecule Rapivab (peramivir injection) Dec-14
For chronic weight management Novo Nordisk biologic Saxenda (liraglutide [rDNA origin] injection) Dec-14
For the treatment of type II diabetes mellitus GlaxoSmithKline biologic Tanzeum (albiglutide) Apr-14
For the management of severe chronic pain Purdue Pharma small molecule Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets Jul-14
For the treatment of acute pain Iroko Pharmaceuticals small molecule Tivorbex (indomethacin) Feb-14
To improve glycemic control in type II diabetics Eli Lilly biologic Trulicity (dulaglutide) Sep-14
For the management of acute pain Mallinckrodt Pharmaceuticals small molecule Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release Mar-14
For the treatment of acute otitis externa Alcon small molecule Xtoro (finafloxacin otic suspension) 0.3%; Dec-14
For the treatment of complicated intra-abdominal and urinary tract infections Cubist Pharmaceuticals small molecule Zerbaxa (ceftolozane + tazobactam) Dec-14
Gastroenterology 3 small molecules 2 biologics
For the prevention of chemotherapy-induced nausea and vomiting, Helsinn small molecule Akynzeo (netupitant and palonosetron) Oct-14
For the treatment of gastric cancer Eli Lilly biologic Cyramza (ramucirumab); Apr-14
For the treatment of adults with ulcerative colitis and Crohn’s disease, Millenium Pharmaceuticals biologic Entyvio (vedolizumab) May-14
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain AstraZeneca small molecule Movantik (naloxegol) Sep-14
For the treatment of complicated intra-abdominal and urinary tract infections Cubist Pharmaceuticals small molecule Zerbaxa (ceftolozane + tazobactam) Dec-14
Genetic Disease 2 small molecule 2 biologic
For the treatment of hemophilia B Biogen Idec biologic Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Mar-14
For the treatment of certain adult patients with Gaucher disease type 1 Genzyme small molecule Cerdelga (eliglustat) Aug-14
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome Upsher-Smith Laboratories small molecule Qudexy XR (topiramate) Mar-14
For the treatment of Mucopolysaccharidosis type IVA BioMarin biologic Vimizim (elosulfase alfa) Feb-14
Healthy Volunteers 1 biologic
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) Apr-14
Hematology 4 small molecule 6 biologics
For the treatment of hemophilia B Biogen Idec biologic Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein]; Mar-14
For the treatment of relapsed or refractory peripheral T-cell lymphoma Spectrum Pharmaceuticals small molecule Beleodaq (belinostat) Jul-14
For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia Amgen biologic Blincyto (blinatumomab) Dec-14
For the treatment of hemophillia A Biogen Idec biologic Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] ; Jun-14
For the treatment of chronic lymphocytic leukemia Pharmacyclics small molecule Imbruvica (ibrutinib) Feb-14
For the treatment of acquired hemophilia A Baxter biologic Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] Oct-14
For the treatment of hereditary angioedema Pharming Group biologic Ruconest (C1 esterase inhibitor [recombinant]) Jul-14
For the treatment of multicentric Castleman’s disease Janssen Biotech biologic Sylvant (siltuximab); Apr-14
For the reduction of thrombotic cardiovascular events Merck small molecule Zontivity (vorapaxar) May-14
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma Gilead small molecule Zydelig (idelalisib) Jul-14
Immunology 3 small molecules 9 biologics
For the treatment of adults with ulcerative colitis and Crohn’s disease Millenium Pharmaceuticals biologic Entyvio (vedolizumab) May-14
For the treatment of grass pollen-induced allergic rhinitis Merck biologic Grastek (Timothy Grass Pollen Allergen Extract); Apr-14
For the treatment of Primary Immunodeficiency Baxter biologic HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Sep-14
For the treatment of chronic obstructive pulmonary disease GlaxoSmithKline small molecule Incruse Ellipta (umeclidinium inhalation powder); May-14
For the treatment of congenital or acquired generalized lipodystrophy Bristol-Myers Squibb biologic Myalept (metreleptin for injection) Feb-14
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) Apr-14
For the treatment of adults with active psoriatic arthritis Celgene small molecule Otezla (apremilast) Mar-14
For the treatment of moderate to severe plaque psoriasis Celgene small molecule Otezla (apremilast) Sep-14
For the treatment of relapsing multiple sclerosis Biogen Idec biologic Plegridy (peginterferon beta-1a) Aug-14
For the treatment of short ragweed pollen-induced allergic rhinitis Merck biologic Ragwitek (Short Ragweed Pollen Allergen Extract) Apr-14
For the treatment of multicentric Castleman’s disease Janssen Biotech biologic Sylvant (siltuximab) Apr-14
For the treatment of HIV-1 ViiV HealthCare biologic Triumeq (abacavir, dolutegravir, and lamivudine); Aug-14
Infections and Infectious Diseases 13 small molecules 0 biologics
For the treatment of acute bacterial skin and skin structure infections Durata Therapeutics semisynthetic small molecule Dalvance (dalbavancin) May-14
For the treatment of hepatitis C, Gilead small molecule Harvoni (ledipasvir and sofosbuvir) Oct-14
For the treatment of visceral, cutaneous and mucosal leishmaniasis Knight Therapeutics small molecule Impavido (miltefosine) Mar-14
For the treatment of onychomycosis of the toenails Valeant Pharmaceuticals small molecule Jublia (efinaconazole) 10% topical gel Jun-14
For the treatment of onychomycosis of the toenails Anacor small molecule Kerydin (tavaborole) Jul-14
For the treatment of bacterial vaginosis Actavis, Inc small molecule Metronidazole 1.3% Vaginal Gel Apr-14
For the treatment of acute bacterial skin and skin structure infections The Medicines Company semisynthetic small molecule Orbactiv (oritavancin) Aug-14
For the treatment of acute uncomplicated influenza in adults Biocryst small molecule Rapivab (peramivir injection) Dec-14
For the treatment of acute bacterial skin and skin structure infections Cubist Pharmaceuticals small molecule Sivextro (tedizolid phosphate) Jun-14
For the treatment of HIV-1 ViiV HealthCare small molecule Triumeq (abacavir, dolutegravir, and lamivudine) Aug-14
; For the treatment of genotype 1 chronic hepatitis C virus Abbvie small molecule Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets; Dec-14
For the treatment of acute otitis externa Alcon small molecule Xtoro (finafloxacin otic suspension) 0.3% Dec-14
For the treatment of complicated intra-abdominal and urinary tract infections Cubist Pharmaceuticals small molecule Zerbaxa (ceftolozane + tazobactam) Dec-14
Internal Medicine 1 small molecule
For the treatment of certain adult patients with Gaucher disease type 1, Genzyme small molecule Cerdelga (eliglustat); Aug-14
Musculoskeletal 2 small molecule 3 biologic
For the treatment of relapsing multiple sclerosis Genzyme biologic Lemtrada (alemtuzumab) Nov-14
For the treatment of adults with active psoriatic arthritis Celgene small molecule Otezla (apremilast) Mar-14
For the treatment of relapsing multiple sclerosis Biogen Idec biologic Plegridy (peginterferon beta-1a) Aug-14
For the management of severe chronic pain Purdue Pharma small molecule Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets Jul-14
For the treatment of Mucopolysaccharidosis type IVA BioMarin biologic Vimizim (elosulfase alfa) Feb-14
Nephrology 3 small molecule
For the treatment of hyperphosphatemia in patients with chronic kidney disease Keryx Biopharma small molecule Auryxia (Ferric citrate) Sep-14
For the treatment of hepatitis C Gilead small molecule Harvoni (ledipasvir and sofosbuvir) Oct-14
For the treatment of genotype 1 chronic hepatitis C virus Abbvie small molecule Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir) tablets Dec-14
Neurology 10 small molecules 2 biologics
For the treatment of insomnia Merck small molecule Belsomra (suvorexant) Aug-14
For the management of mild, moderate or severe pain Hospira small molecule Dyloject (diclofenac sodium) Injection Dec-14
For the treatment of non-24-hour sleep-wake disorder in the totally blind Vanda Pharmaceuticals small molecule Hetlioz (tasimelteon) Jan-14
For the treatment of relapsing multiple sclerosis Genzyme biologic Lemtrada (alemtuzumab) Nov-14
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain AstraZeneca small molecule Movantik (naloxegol) Sep-14
For the treatment of moderate to severe dementia of the Alzheimer’s type Forest Laboratories small molecule Namzaric (memantine hydrochloride extended-release + donepezil hydrochloride) Dec-14
For the treatment of neurogenic orthostatic hypotension Chelsea Therapeutics small molecule Northera (droxidopa) Feb-14
For the treatment of relapsing multiple sclerosis Biogen IDEC biologic Plegridy (peginterferon beta-1a) Aug-14
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome Upsher-Smith Laboratories small molecule Qudexy XR (topiramate) Mar-14
For the management of severe chronic pain Purdue Pharma small molecule Targiniq ER (oxycodone hydrochloride + naloxone hydrochloride) extended-release tablets Jul-14
For the treatment of acute pain Iroko Pharmaceuticals small molecule Tivorbex (indomethacin) Feb-14
For the management of acute pain Mallinckrodt Pharmaceuticals small molecule Xartemis XR (oxycodone hydrochloride and acetaminophen) extended release Mar-14
Nutrition and Weight Loss 2 small molecule 3 biologics
For chronic weight management Takeda Pharmaceuticals U.S.A small molecule Contrave (naltrexone HCl and bupropion HCl) Sep-14
For the treatment of type II diabetes Boehringer Ingelheim small molecule Jardiance (empagliflozin) Aug-14
For chronic weight management Novo Nordisk biologic Saxenda (liraglutide [rDNA origin] injection) Dec-14
For the treatment of type II diabetes mellitus GlaxoSmithKline biologic Tanzeum (albiglutide) Apr-14
To improve glycemic control in type II diabetics Eli Lilly biologic Trulicity (dulaglutide) Sep-14
Obstetrics/Gynecology (Women’s Health) 2 small molecule
For the treatment of previously treated BRCA mutated advanced ovarian cancer, AstraZeneca small molecule Lynparza (olaparib) Dec-14
For the treatment of bacterial vaginosis Actavis, Inc small molecule Metronidazole 1.3% Vaginal Gel Apr-14
Oncology 6 small molecules 4 biologics
For the prevention of chemotherapy-induced nausea and vomiting Helsinn small molecule Akynzeo (netupitant and palonosetron) Oct-14
For the treatment of relapsed or refractory peripheral T-cell lymphoma Spectrum Pharmaceuticals small molecule Beleodaq (belinostat) Jul-14
For the treatment of Philadelphia chromosome-negative relapsed /refractory B cell precursor acute lymphoblastic leukemia Amgen biologic Blincyto (blinatumomab) Dec-14
For the treatment of gastric cancer Eli Lilly biologic Cyramza (ramucirumab) Apr-14
For the treatment of chronic lymphocytic leukemia Pharmacyclics small molecule Imbruvica (ibrutinib) Feb-14
For the treatment of unresectable or metastatic melanoma Merck biologic Keytruda (pembrolizumab) Sep-14
For the treatment of previously treated BRCA mutated advanced ovarian cancer AstraZeneca small molecule Lynparza (olaparib) Dec-14
For the treatment of unresectable or metastatic melanoma Bristol-Myers Squibb biologic Opdivo (nivolumab) Dec-15
For the treatment of relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma Gilead small molecule Zydelig (idelalisib) Jul-14
For the treatment of ALK+ metastatic non-small cell lung cancer Novartis small molecule Zykadia (ceritinib) Apr-14
Ophthalmology 2 small molecule 1 biologic
For the treatment of non-24-hour sleep-wake disorder in the totally blind Vanda Pharmaceuticals small molecule Hetlioz (tasimelteon) Jan-14
For use during eye surgery to prevent intraoperative miosis and reduce post-operative pain Omeros small molecule Omidria (phenylephrine and ketorolac injection) Jun-14
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) Apr-14
Orthopedics/Orthopedic Surgery 1 small molecule
For the treatment of adults with active psoriatic arthritis Celgene small molecule Otezla (apremilast) Mar-14
Otolaryngology (Ear, Nose, Throat) 1 small molecule 3 biologic
For the treatment of grass pollen-induced allergic rhinitis Merck biologic Grastek (Timothy Grass Pollen Allergen Extract) Apr-14
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) 14-Apr
For the treatment of short ragweed pollen-induced allergic rhinitis Merck biologic Ragwitek (Short Ragweed Pollen Allergen Extract) Apr-14
For the treatment of acute otitis externa Alcon small molecule Xtoro (finafloxacin otic suspension) 0.3% Dec-14
Pediatrics/Neonatology 2 small molecule 2 biologics
; For the treatment of hemophilia B Biogen Idec biologic Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] Mar-14
For the treatment of asthma GlaxoSmithKline small molecule Arnuity Ellipta (fluticasone furoate inhalation powder) Aug-14
For the treatment of partial onset and primary generalized tonic-clonic seizures and Lennox-Gastaut Syndrome Upsher-Smith Laboratories small molecule Qudexy XR (topiramate) Mar-14
For the treatment of Mucopolysaccharidosis type IVA BioMarin biologic Vimizim (elosulfase alfa) Feb-14
Pharmacology/Toxicology 3 small molecule 1 biologic
For the prevention of chemotherapy-induced nausea and vomiting Helsinn small molecule Akynzeo (netupitant and palonosetron) Oct-14
For the maintenance treatment of opioid dependence BioDelivery Sciences small molecule Bunavail (buprenorphine and naloxone) Jun-14
For the treatment of opiod-induced constipation in adults with chronic non-cancer pain AstraZeneca small molecule Movantik (naloxegol) Sep-14
For the treatment of congenital or acquired generalized lipodystrophy Bristol-Myers Squibb biologic Myalept (metreleptin for injection) Feb-14
Psychiatry/Psychology 1 small molecule
For the maintenance treatment of opioid dependence BioDelivery Sciences small molecule Bunavail (buprenorphine and naloxone) Jun-14
Pulmonary/Respiratory Diseases 6 small molecule 3 biologic
For the treatment of asthma GlaxoSmithKline small molecule Arnuity Ellipta (fluticasone furoate inhalation powder) Aug-14
For the treatment of idiopathic pulmonary fibrosis InterMune small molecule Esbriet (pirfenidone) Oct-14
For the treatment of grass pollen-induced allergic rhinitis Merck biologic Grastek (Timothy Grass Pollen Allergen Extract) Apr-14
For the treatment of chronic obstructive pulmonary disease GlaxoSmithKline small molecule Incruse Ellipta (umeclidinium inhalation powder) May-14
For the treatment of idiopathic pulmonary fibrosis Boehringer Ingelheim small molecule Ofev (nintedanib) Oct-14
For the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis Greer Labs biologic Oralair (Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass Mixed Pollens Allergen Extract) Apr-14
For the treatment of short ragweed pollen-induced allergic rhinitis Merck biologic Ragwitek (Short Ragweed Pollen Allergen Extract) Apr-14
For the treatment of chronic obstructive pulmonary disease Boehringer Ingelheim small molecule Striverdi Respimat (olodaterol) Jul-14
For the treatment of ALK+ metastatic non-small cell lung cancer Novartis small molecule Zykadia (ceritinib) Apr-14
Rheumatology 1 small molecule
For the treatment of adults with active psoriatic arthritis Celgene small molecule Otezla (apremilast) Mar-14
Sleep 1 small molecule
For the treatment of non-24-hour sleep-wake disorder in the totally blind Vanda Pharmaceuticals small molecule Hetlioz (tasimelteon) Jan-14
Urology 1 small molecule
For the treatment of complicated intra-abdominal and urinary tract infections Cubist Pharmaceuticals small molecule Zerbaxa (ceftolozane + tazobactam) Dec-14

 

SOURCE

https://www.centerwatch.com/drug-information/fda-approved-drugs/year/2014

Read Full Post »

« Newer Posts - Older Posts »